Eli Lilly Acquires Akouos to Advance Gene Therapies for Hearing Loss

Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics

August 31, 2020

Biotechnology

Ionis Pharmaceuticals agreed to acquire the approximately 24% of Akcea Therapeutics it does not already own for $18.15 per share in cash, implying a fully diluted transaction value of about $500 million. The deal will be executed via a tender offer followed by a second-step merger, and Ionis expects to complete the transaction in Q4 2020 to consolidate Akcea's pipeline, commercial products and cash while realizing cost synergies.

Eli Lilly Acquires Sigilon Therapeutics

June 29, 2023

Biotechnology

Eli Lilly agreed to acquire Sigilon Therapeutics in a cash tender offer valuing the biotech at roughly $34.6 million up front plus contingent value rights that could increase total consideration to about $309.6 million. The acquisition brings Sigilon's encapsulated cell therapy platform (including SIG-002 for type 1 diabetes) into Lilly's diabetes and cell-therapy R&D efforts to accelerate development and potential commercialization.

Sonova Acquires Alpaca Audiology to Expand U.S. Presence

January 13, 2022

Healthcare Services

Sonova Holding AG has agreed to acquire Alpaca Audiology, a U.S. network of approximately 220 audiology clinics with over 500 employees, for USD 310 million on a cash- and debt-free basis. The deal, financed from Sonova’s cash balance and subject to regulatory approval, is intended to substantially increase Sonova’s direct consumer access in the United States and is expected to close before the end of financial year 2021/22.

EssilorLuxottica Acquires French AI Hearing Startup Pulse Audition

January 2, 2025

Healthcare Services

EssilorLuxottica has acquired Pulse Audition, a French AI-driven startup that develops noise-reduction and speech-enhancement technology for wearable devices. The purchase brings Pulse Audition's embedded-AI audio signal processing capabilities into EssilorLuxottica's hearing solutions roadmap to enable AI-powered speech enhancement in glasses and other wearable products.

AbbVie to Acquire ImmunoGen for $10.1 Billion

November 30, 2023

Biotechnology

AbbVie has entered into a definitive agreement to acquire ImmunoGen for $31.26 per share in cash, valuing the company at approximately $10.1 billion. The deal gives AbbVie commercial rights to ELAHERE (mirvetuximab soravtansine-gynx) and ImmunoGen's ADC pipeline, expanding AbbVie's oncology capabilities; the transaction is expected to close in mid-2024 subject to shareholder and regulatory approvals.

GSK Acquires Aiolos Bio for Up to $1.4 Billion

January 9, 2024

Biotechnology

GSK will acquire clinical-stage biopharmaceutical company Aiolos Bio for $1 billion upfront and up to $400 million in regulatory milestone payments, gaining access to AIO-001, a long-acting anti-TSLP monoclonal antibody advancing into Phase II for asthma. The deal expands GSK's respiratory biologics pipeline with a potential best-in-class therapy that may offer dosing as infrequently as every six months.